이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

TollB-001의 단일 및 다중 경구 투여에 관한 연구

2026년 9월 28일 업데이트: Toll Biotech Co. Ltd. (Beijing)

단일 및 다중 경구 투여량의 안전성, 내약성, 약동학, 약력학을 평가하고 TollB-001의 식품 효과를 평가하기 위한 무작위 배정, 이중 맹검, 위약 대조, 용량 증량 연구 1상

The primary objective is to evaluate the safety and tolerability of TollB-001 following the administration of single or multiple oral doses in healthy adult subjects

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

This is a Phase I, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and PD of single or multiple dose(s) of TollB-001 administered orally in healthy adult subjects and the food effect on the PK of a single dose of TollB-001 with a randomized, open-label and two-period crossover design.

This study includes three parts. Part A: single ascending dose (SAD) study; Part B: multiple ascending dose (MAD) study; and Part C: FE study.

연구 유형

중재적

등록 (실제)

98

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Sichuan
      • Chengdu, Sichuan, 중국, 611130
        • Chengdu Fifth People's Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Healthy male and female subjects between the age of 18 and 45 (both inclusive) when signing the informed consent form (ICF)
  2. Able to give a signed written ICF (the consent form must be signed by the subject prior to any study-specific procedures); have a full understanding of the study content, procedures, and possible AEs; and be willing and able to comply with study procedures and follow-up examinations
  3. Body mass index (BMI, weight [kg]/height2 [m2]) within 19.0-26.0 kg/m2 (both inclusive), with total body weight > 50 kg for male subjects and > 45 kg for female subjects.
  4. The subjects must be willing to use efficient physical contraception methods with a contraceptive failure rate of<1% with their reproductive age partners within 90 days from signing the ICF to the last administration of the investigational drug (such as condoms , intrauterine devices)
  5. Male subjects must also be willing to refrain from donating sperm for 90 days from the first administration of the investigational drug to the last administration of the investigational drug
  6. Results of vital signs, physical examination, laboratory examinations, abdominal and urinary B-ultrasound, 12-lead ECG, and other examination are normal or abnormal but not clinically significant. QT interval corrected for heart rate according to Fridericia's formula (QTcF) must be within the following ranges: QTcF ≤ 450 msec for male subjects, and QTcF ≤ 470 msec for female subjects. Assessment may be repeated if deemed appropriate by the investigator.
  7. Ability to swallow all IMPs.

Exclusion Criteria:

Subjects were excluded if they meet any of the following exclusion criteria:

  1. Known or suspected allergy or hypersensitivity to any component of TollB-001, known allergic constitution or allergy to two or more foods or drugs.
  2. Severe gastrointestinal diseases, such as patients who have undergone major gastrointestinal surgery that would potentially alter absorption and/or excretion of orally administered drugs (except for cholecystectomy, appendectomy, hernia repair), or medical history of ulcer, gastrointestinal bleeding, gastritis, etc.
  3. History or clinical manifestations of any clinically significant gastrointestinal, gallbladder or biliary tract, renal, urologic, pulmonary, neurological, cardiovascular, endocrinological, hematological, immunologic, dermatologic, metabolic disorder, or psychiatric disease (as determined by the investigator).
  4. Current or chronic history of liver disease or known hepatic ,or clinically significant of biliary abnormalities , or clinically significant abnormal results of liver function test at screening, including alanine amino transferase (ALT) or/and aspartate aminotransferase (AST) > 1.5 × upper limit of normal (ULN)or/and total bilirubin > ULN.
  5. eGFR < 90 mL/min/1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at screening or on Day-1.
  6. Current or history of clinically significant cardiac arrhythmias (symptomatic or asymptomatic).
  7. Serious infection within 3 months prior to dosing or symptoms of infection within 7 days before dosing, including acute and chronic infections and local infections (bacterial, viral, parasitic, fungal, or other opportunistic pathogens), which is inappropriate to participant as deemed by the investigator.
  8. Major illness or surgery within 3 months before dosing ,or planned surgery during the study period.
  9. Intolerance to venipuncture.
  10. Participation in any clinical study or received any other investigational product or device within 4 weeks prior to the first dose or 5 times the half-life of the specific drug/biologics(whichever is longer), or plan to take an investigational agent during the study.
  11. Donated blood > 400 mL or significant blood loss (equivalent to 400 mL), or received blood transfusion within 3 months of prior to screening, or have plans to donate blood during the study.
  12. History of malignancy within 5 years prior to screening (excluding non-melanoma skin cancer that has been resected).
  13. Positive results of any of the following tests at screening: serum hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV RNA or HCV antibodies [Ab]), human immunodeficiency virus 1 and 2 (HIV)Ab, or Treponema pallidum (TP) Ab.
  14. Active tuberculosis (TB) infection indicated by chest radiography orγ-interferon at screening or within 3 months prior to screening. TB test positive, or active or latent TB infection as discretion of the investigator according to clinical practice, or history of TB, or currently receiving treatment for this disease.
  15. Plans to receive administration of any live vaccine within 4 weeks before dosing or up to 30 days after the last dose of IMP.
  16. Use of drugs, including prescription, over-the-counter medications herbal products, vitamins, and minerals, within 2 weeks prior to the first dose or within 5 times the elimination half-life of the medication prior to first dosing(whichever is longer).
  17. Participated in strenuous exercise from 48 hours prior to Day-1 .
  18. Unwilling to refrain from any food or beverage containing caffeine or producing xanthine after metabolism (e.g., tea, coffee, chocolate, cola, red cattle) from 24 hours prior to Day -1 and during the study.
  19. Use of food or beverages likely to influence liver metabolism, within 14 days prior to the first dose of the IMP (e.g., star fruit, pomelos, grapefruit, and Seville oranges). Use of any drugs or nutrients known to modulate cytochrome P450 (CYP) 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A and transporter OATP1B1,1B3, OAT3, OCT2 activity (refer to Appendix 3) or any strong or moderate inhibitors or inducers ofCYP1A2, BCRP, OATP1B1, OATP1B3, and OAT3 (refer to Appendix 4) starting from 14 days priorto dose administration on Day 1.
  20. History of significant alcohol abuse within 6 months prior to screening or use of more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of alcohol 40% or 150 mL of wine) within 90 days prior to screening or alcohol breath test >0.0mg/100ml at screening, or unwilling to refrain from consumption of alcohol during the study.
  21. Use of tobacco or nicotine products or smoking within 90 days (more than 5 cigarettes per day) prior to screening and unwilling to refrain from 24 hours prior to Day -1 and during the study.
  22. Drug abuse or those who have taken drugs (such as cocaine, phencyclidine, etc.) within one year prior to screening (consultation); Or those who are positive for urine drug abuse screening (methamphetamine, ketamine, MDMA ,tetrahydrocannabinoid acid, morphine) during screening.
  23. Women who are lactating or positive pregnancy test within at screening or during the study period, or planning to become pregnant during the study period.
  24. Acute illness occurs or concomitant medication required from screening to dosing.
  25. Constipated or irregular bowel movements.
  26. Any other situation that researchers believe may affect the subject's ability to provide informed consent or follow the trial protocol, or the subject's participation in the trial may affect the trial results or their own safety.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: SAD-TollB-001 50mg Dosage groups

drug:TollB-001 tablets(50mg,single-dose, on the first day)

TollB-001 treatment

다른 이름들:
  • 톨비-001

TollB-001 Placebo

실험적: SAD-TollB-001 100mg Dosage groups

drug:TollB-001 tablets (100mg,single-dose, on the first day)

TollB-001 treatment

다른 이름들:
  • 톨비-001

TollB-001 Placebo

실험적: SAD-TollB-001 200mg Dosage groups

drug:TollB-001 tablets (200mg,single-dose, on the first day)

TollB-001 treatment

다른 이름들:
  • 톨비-001

TollB-001 Placebo

실험적: SAD-TollB-001 400mg Dosage groups

drug:TollB-001 tablets (400mg,single-dose, on the first day)

TollB-001 treatment

다른 이름들:
  • 톨비-001

TollB-001 Placebo

실험적: SAD-TollB-001 800mg Dosage groups

drug:TollB-001 tablets (600mg,single-dose, on the first day)

TollB-001 treatment

다른 이름들:
  • 톨비-001

TollB-001 Placebo

실험적: MAD- TollB-001 100mg Dosage groups

drug:TollB-001 tablets (50mg,Multiple-dose, once per day for 10 days)

TollB-001 treatment

다른 이름들:
  • 톨비-001

TollB-001 Placebo

실험적: MAD- TollB-001 200mg Dosage groups

drug:TollB-001 tablets (100mg,Multiple-dose, once per day for 10 days)

TollB-001 treatment

다른 이름들:
  • 톨비-001

TollB-001 Placebo

실험적: MAD-TollB-001 400mg Dosage groups

drug:TollB-001 tablets (200mg,Multiple-dose, once per day for 10 days)

TollB-001 treatment

다른 이름들:
  • 톨비-001

TollB-001 Placebo

실험적: MAD-TollB-001 800mg Dosage groups

drug:TollB-001 tablets (400mg,Multiple-dose, once per day for 10 days)

TollB-001 treatment

다른 이름들:
  • 톨비-001

TollB-001 Placebo

실험적: FE-Low Dosage groups

drug:TollB-001 tablets(Subjects in the fasting-fed sequence group will be administered with TollB-001 under fasting condition in the first period and under fed condition in the second period; subject in the fed-fasting sequence group will be administered with TollB-001 under fed condition in the first period and under fasting condition in the second period. The two periods of cross-administration will have a washout period of 10 days)

TollB-001 treatment

다른 이름들:
  • 톨비-001
실험적: FE-High Dosage groups

drug:TollB-001 tablets Subjects in the fasting-fed sequence group will be administered with TollB-001 under fasting condition in the first period and under fed condition in the second period; subject in the fed-fasting sequence group will be administered with TollB-001 under fed condition in thefirst period and under fasting condition in the second period. The two periods of cross-administration will have a washout period of 10 days)

TollB-001 treatment

다른 이름들:
  • 톨비-001

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Red blood cell count(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

Red blood cell count

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
hematocrit(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

hematocrit

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
hemoglobin(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

hemoglobin

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
white blood cell count(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

white blood cell count

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
whiteblood cell differential count(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

whiteblood cell differential count

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
plateletcount(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

plateletcount

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
Alanine aminotransferase(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

Alanine aminotransferase

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
aspartateaminotransferase(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

aspartateaminotransferase

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
alkaline phosphatase(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

alkaline phosphatase

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
gamma-glutamyl transpeptidase(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

gamma-glutamyl transpeptidase

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
total bilirubin(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

total bilirubin

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
direct bilirubin(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

direct bilirubin

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
blood ureanitrogen (or blood urea)(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

blood ureanitrogen (or blood urea)

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
creatinine(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

creatinine

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
glucose(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

glucose

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
total protein(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

total protein

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
creatine kinase(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

creatine kinase

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
Activated partial thromboplastin time(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

Activated partial thromboplastin time

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
prothrombin time(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

prothrombin time

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
internationalnormalized ratio(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

internationalnormalized ratio

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
fibrinogen(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

fibrinogen

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
urine pH(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

urine pH

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
urine specific gravity(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

urine specific gravity

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
urine glucose(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

urine glucose

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
urine protein(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

urine protein

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
urobilinogen(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

urobilinogen

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
urine bilirubin(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

urine bilirubin

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
urine leukocyte(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

urine leukocyte

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
urine ketone body(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

urine ketone body

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
urine red blood cells(physiological parameter) by investigator
기간: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

urine red blood cells

Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)
AE/SAE monitoring by ToxicityGrading Scale for Healthy Adults and Volunteers Enrolled in Preventative Vaccine Trials,2007 (70 FR 22664)
기간: First dose up to last follow-up visit(for a maximum of 20 days)

AE/SAE monitoring

First dose up to last follow-up visit(for a maximum of 20 days)
physical examination(physiological parameter) by investigator
기간: First dose up to last follow-up visit(for a maximum of 20 days);SAD:Screening,Day2,Day5 or ET Visit;MAD:Screening,Day3,Day6,Day9 ,Day11,Day14or ET Visit;FE:Screening,Period 1 Day2,Period 1 Day5;Period 2 Day-1,Period 2 Day2,Period 2 Day5 or ET Visit.

The assessments of general appearance, head(including ears, eyes, nose, throat), neck, skin, cardiovascular system, respiratory system,abdominal system, nervous system, musculoskeletal system, and lymphatic system

First dose up to last follow-up visit(for a maximum of 20 days);SAD:Screening,Day2,Day5 or ET Visit;MAD:Screening,Day3,Day6,Day9 ,Day11,Day14or ET Visit;FE:Screening,Period 1 Day2,Period 1 Day5;Period 2 Day-1,Period 2 Day2,Period 2 Day5 or ET Visit.
blood pressure(systolic pressure and diastolic pressure)(physiological parameter) by investigator
기간: For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 to Day14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.

blood pressure(systolic pressure and diastolic pressure)

For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 to Day14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.
pulse(physiological parameter) by investigator
기간: For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.

pulse

For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.
respiratory rate(physiological parameter) by investigator
기간: For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.

respiratory rate

For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.
body temperature(physiological parameter) by investigator
기간: For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.

body temperature

For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.
12-lead ECGs
기간: For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 to Day14 or ET Visit;FE:Screening,Period 1 Day1,Period 1 Day3,Period 1 Day5;Period 2 Day-1,Period 2 Day1,Period 2 Day3,Period 2 Day5 or ET Visit.

ECGs done in triplicate; heart rate, PR interval, QT and QTc interval and QRS duration

For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 to Day14 or ET Visit;FE:Screening,Period 1 Day1,Period 1 Day3,Period 1 Day5;Period 2 Day-1,Period 2 Day1,Period 2 Day3,Period 2 Day5 or ET Visit.
B-ultrasound(physiological parameter) by investigator
기간: For a maximum of 20 days;SAD:Screening,Day5 or ET Visit;MAD:Screening,Day14 or ET Visit;FE:Screening,Period 1 Day5;Period 2 Day5 or ET Visit.

liver, gallbladder, spleen, pancreas, kidney and bladder

For a maximum of 20 days;SAD:Screening,Day5 or ET Visit;MAD:Screening,Day14 or ET Visit;FE:Screening,Period 1 Day5;Period 2 Day5 or ET Visit.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: wen he, Chengdu Fifth People's Hospital

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 9월 28일

기본 완료 (실제)

2025년 4월 7일

연구 완료 (실제)

2025년 4월 7일

연구 등록 날짜

최초 제출

2023년 9월 22일

QC 기준을 충족하는 최초 제출

2023년 10월 22일

처음 게시됨 (실제)

2023년 10월 27일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 28일

마지막으로 확인됨

2023년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • TLBT-TOLLB-001-I

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .